Evolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Earnings Management Comments

Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q BeatNovember 5, 2019 7:22 AM Evolus Reports Third Quarter 2019 Financial Results and Provides Business UpdateNovember 4, 2019 7:00 AM AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox salesNovember 1, 2019 7:52 AM